Business Wire

OLYMPUS

6.5.2021 08:02:32 CEST | Business Wire | Press release

Share
Olympus Targets Carbon Neutrality by 2030

Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today it is targeting carbon neutrality by 2030, while also agreeing with recommendations by the Task Force on Climate-Related Financial Disclosures (TCFD), and adding carbon neutrality and enabling a circular economy to its environmental, societal and governance (ESG) enhancement measures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505006248/en/

Olympus has in place a variety of environmental initiatives across its global operations. However, the company is acutely aware of the damaging effects of climate change on natural ecosystems. For this reason, it has added carbon neutrality and enabling a circular economy as an additional ESG materiality criterion.

In its corporate strategy announced in November 2019, Olympus listed four distinct ESG criteria as material ESG enhancement measures: (1) healthcare access and outcomes; (2) compliance, product quality and safety; (3) responsible supply chain; and (4) diversity and inclusion. To these four will be added the new criterion.

Target of Carbon Neutrality by 2030

Olympus set a target of achieving carbon neutrality by 2030 with zero CO2 emissions from its entire business operation. Olympus has already introduced a wide range of initiatives to reduce CO2 emissions, which since 2010 includes procuring 100% of its electricity requirements from renewable sources where it manufactures in Europe and the U.S.

Going forward, Olympus will continue to improve its manufacturing process and the energy-saving measures to achieve carbon neutrality. At the same time, it will accelerate the efforts to reduce CO2 by switching all the electricity procurement for all of its business operations1 to renewable energy sources by 2030.

Support for the Recommendations of TCFD

The TCFD is an international organization that was established in December 2015 by the Financial Stability Board (FSB) to develop the framework for companies to disclose climate-related risks to financial markets. In 2017, the TCFD issued recommendations for use by companies in disclosing pertinent information about risks and opportunities related to climate change to investors, lenders, insurers and other participants in the market so that they can have a more complete picture when assessing the value of those companies and the risks they face. The initiatives of the TCFD are highly evaluated for encouraging sustainable investments to build an economy which is resilient in the face of climate-related uncertainty. Around 1,900 companies and institutions (as of March 25, 2021) have announced their support of the recommendations by the TCFD. (https://www.fsb-tcfd.org/ )

Olympus’ initiatives to reduce its environmental impact and ensure transparent communication about those initiatives fall under its Environmental Health and Safety Policy. The company actively disseminates information about its environmental activities both internally and externally. This includes identifying and disclosing the environmental impact of its business activities.

Olympus strives to promote a mutual understanding about the importance of ESG materiality with stakeholders. Recognizing that climate change is a major issue that affects business operations, Olympus is advancing activities to deal with environmental risks, contributing to carbon tax and complying with other related regulations. Olympus will continue to advance dialogue with stakeholders, and proactively disclose information based on the TCFD recommendations.

_____________

1

Excluding small sales offices rented locally

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye